Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
28M
-
Number of holders
-
42
-
Total 13F shares, excl. options
-
2.48M
-
Shares change
-
+542K
-
Total reported value, excl. options
-
$25.3M
-
Value change
-
+$4.76M
-
Put/Call ratio
-
0.85
-
Number of buys
-
23
-
Number of sells
-
-17
-
Price
-
$10.20
Significant Holders of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) as of Q4 2021
54 filings reported holding INMB - Inmune Bio, Inc. - Common Stock, par value $0.001 per share as of Q4 2021.
Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB) has 42 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.48M shares
of 28M outstanding shares and own 8.88% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (511K shares), MORGAN STANLEY (378K shares), BlackRock Inc. (233K shares), ACT CAPITAL MANAGEMENT, LLC (231K shares), MILLENNIUM MANAGEMENT LLC (151K shares), GEODE CAPITAL MANAGEMENT, LLC (118K shares), Janney Montgomery Scott LLC (114K shares), DEUTSCHE BANK AG\ (106K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (90.6K shares), and CITADEL ADVISORS LLC (67.9K shares).
This table shows the top 42 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.